Drug Type Small molecule drug |
Synonyms Naluzotan, Naluzotan hydrochloride (USAN), PRX-00023 |
Target |
Action agonists |
Mechanism 5-HT1A receptor agonists(Serotonin 1a (5-HT1a) receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC23H39ClN4O3S |
InChIKeyQBACIVGQRFVOBZ-UHFFFAOYSA-N |
CAS Registry740873-82-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09359 | Naluzotan Hydrochloride | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Generalized anxiety disorder | Phase 3 | United States | 01 Aug 2005 | |
Anxiety Disorders | Phase 3 | - | - | |
Anxiety Disorders | Phase 3 | - | - | |
Anxiety Disorders | Phase 3 | - | - | |
Epilepsy, Temporal Lobe | Phase 2 | United States | 07 Jan 2011 | |
Depressive Disorder, Major | Phase 2 | United States | 01 Mar 2007 | |
Epilepsy | Phase 2 | - | - | |
Epilepsy | Phase 2 | - | - | |
Dyskinesia, Drug-Induced | Phase 1 | United States | - |